Skip to main content

Table 2 Efficacy of ALK inhibitors according to ALK fusion variants

From: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants

  Total (N = 52) EML4-ALK variant 1 (N = 20) EML4-ALK variant 2 (N = 3) EML4-ALK variant 3a/b (N = 10) Non-EML4 variants (N = 19) P value
First-line, platinum-based CTx, N (%) 40 (76.9) 17 (85.0) 1 (33.3) 9 (90.0) 13 (68.4) 0.979
 PR 10 (25.0) 4 (23.5) 0 (0.0) 3 (33.3) 3 (23.1)  
 SD 20 (50.0) 9 (52.9) 1 (100.0) 4 (44.4) 6 (46.2)  
 PD 10 (25.0) 4 (23.5) 0 (0.0) 2 (22.2) 4 (30.8)  
 ORR, % 25.0 23.5 0.0 33.3 23.1 0.853
 DCR, % 75.0 76.5 100.0 77.8 69.2 0.791
Received pemetrexed, any line, N (%) 35 (67.3) 17 (85.0) 1 (33.3) 6 (60.0) 11 (57.9) 0.591
 PR 7 (20.0) 2 (11.8) 0 (0.0) 3 (50.0) 2 (18.2)  
 SD 25 (71.4) 13 (76.5) 1 (100.0) 3 (50.0) 8 (72.7)  
 PD 3 (8.6) 2 (11.8) 0 (0.0) 0 (0.0) 1 (9.1)  
 ORR, % 20.0 11.8 0.0 50.0 18.2 0.291
 DCR, % 91.4 88.2 100.0 100.0 90.9 1.000
Received Crizotinib, N (%) 32 (61.5) 10 (50.0) 2 (66.7) 8 (80.0) 12 (63.2) 0.134
 PR 17 (53.1) 3 (30.0) 2 (100.0) 4 (50.0) 8 (66.7)  
 SD 10 (31.3) 5 (50.0) 0 (0.0) 1 (12.5) 4 (33.3)  
 PD 5 (15.6) 2 (20.0) 0 (0.0) 3 (37.5) 0 (0.0)  
 ORR, % 53.1 30.0 100.0 50.0 66.7 0.191
 DCR, % 84.4 80.0 100.0 62.5 100.0 0.109
Received Ceritinib, N (%) 14 (26.9) 5 (25.0) 1 (33.3) 3 (30.0) 5 (26.3) 0.723
 CR 1 (7.1) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)  
 PR 7 (50.0) 2 (40.0) 0 (0.0) 2 (66.7) 3 (60.0)  
 SD 4 (28.6) 2 (40.0) 0 (0.0) 1 (33.3) 1 (20.0)  
 PD 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0)  
 ORR, % 57.1 50.0 100.0 66.7 62.5 NA
 DCR, % 85.7 100.0 100.0 100.0 80.0 NA
Received Alectinib, N (%) 2 (3.8) 0 (0.0) 0 (0.0) 1 (10.0) 1 (5.3) NA
 PR 2 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)  
  1. CTx chemotherapy; PR partial response; SD stable disease; PD progressive disease; CR complete response; ORR objective response rate; DCR disease control rate; NA not applicable